Glatiramer acetate (CAS NO.147245-92-9)
CAS Number:
147245-92-9
Name:
L-Glutamic acid, polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)
Superlist Name:
Glatiramer acetate
Molecular Structure:
Formula:
(C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)x.xC2H4O2
Deleted CAS:
943513-95-9
Synonyms:
L-Alanine,polymer with L-glutamic acid, L-lysine and L-tyrosine, acetate (salt) (9CI);L-Lysine, polymer with L-alanine, L-glutamic acid and L-tyrosine, acetate(salt) (9CI);L-Tyrosine, polymer with L-alanine, L-glutamic acid and L-lysine,acetate (salt) (9CI);Cop 1 (polyamide);Copaxone;Copolymer 1;Glatiramer acetate;L-Glutamic acid peptide with L-alanine, L-lysine andL-tyrosine, acetate (salt);Protiramer;TV 5010;
Assay: 99%
Exterior: White powder
Package: Aluminum bag
Storage: sealed storage in shady and cool warehouse
Specifications
1. Introduction of Glatiramer acetate (CAS NO.147245-92-9)
Glatiramer acetate is a kind of white powder. The chemical name of Glatiramer acetate is acetic acid; 2-amino-3-(4-hydroxyphenyl)propanoic acid; 2-aminopentanedioic acid; 2-aminopropanoic acid; 2,6-diaminohexanoic acid. Glatiramer acetate belongs to pharmaceutical intermediates. It is a random polymer of four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine, and may work as a decoy for the immune system. 943513-95-9 is the deleted CAS NO. of it.
Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.
2. Basic information of Glatiramer acetate (CAS NO.147245-92-9)
1) Properties of Glatiramer acetate
(1)ACD/BCF (pH 5.5): 1.00; (2)ACD/BCF (pH 7.4): 1.00; (3)ACD/KOC (pH 5.5): 1.00; (4)ACD/KOC (pH 7.4): 1.00; (5)# of Rule of 5 Violations: 3; (6)#H bond acceptors: 18; (7)#H bond donors: 17; (8)#Freely Rotating Bonds: 19; (9)Polar Surface Area: 374.13 Å2; (10)Flash Point: 528.7 °C; (11)Enthalpy of Vaporization: 144.95 kJ/mol; (12)Boiling Point: 950.6 °C at 760 mmHg; (13)Vapour Pressure: 0 mmHg at 25°C.
2) The following information could be converted into the structure:
(1) SMILES: Oc1ccc(CC(N)C(O)=O)cc1.CC(O)=O.OC(=O)CCC(N)C(O)=O.NCCCCC(N)C(O)=O.CC(N)C(O)=O
(2) Std. InChI: InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)
(3) Std. InChIKey: FHEAIOHRHQGZPC-UHFFFAOYSA-N
3) Toxicity Data of Glatiramer acetate
Adverse reactions include injection site reactions, vasodilatation, chest pain, asthenia, infection, pain, nausea, arthralgia, anxiety, and hypertonia.
4) Mechanism of action of Glatiramer acetate
Glatiramer acetate is a random polymer (average molecular mass 6.4 kD) composed of four amino acids that are found in myelin basic protein. Glatiramer acetate (GA) exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. Then it will potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression. Furthermore, the GA-specific cells in the brain express the anti-inflammatory cytokines IL-10 and transforming growth factor beta, in addition to brain-derived neurotrophic factor, however they do not express the inflammatory cytokine IFN-gamma. Some studies also suggest that Glatiramer acetate directly inhibits dendritic cells and monocytes - both of which are circulating antigen presenting cells. Glatiramer acetate has been shown in clinical trials to reduce the number and severity of exacerbations.
5) Pharmacodynamics of Glatiramer acetate
Glatiramer acetate was originally designed to mimic a protein in myelin, called myelin basic protein, with the intention of inducing EAE (an animal model of MS). Quite to the contrary, it was found to suppress the disease and as a result came to be trialed in human MS. Glatiramer acetate converts the body's immune response from a Th1 type to a Th2 one, promotes suppressor T cells or acts as an altered peptide ligand. Glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery. Some fraction of the injected material, either intact or partially hydrolyzed, is presumed to enter the lymphatic circulation, enabling it to reach regional lymph nodes, and some may enter the systemic circulation intact.
6) Applications of Glatiramer acetate
Glatiramer acetate can be used for research and clinical trials. Glatiramer acetate is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis. Glatiramer acetate is approved by the Food and Drug Administration (FDA) for reducing the frequency of relapses, but not for reducing the progression of disability. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.
7) Packaging picture of 1Kg Glatiramer acetate
Glatiramer acetate is a kind of white powder. The chemical name of Glatiramer acetate is acetic acid; 2-amino-3-(4-hydroxyphenyl)propanoic acid; 2-aminopentanedioic acid; 2-aminopropanoic acid; 2,6-diaminohexanoic acid. Glatiramer acetate belongs to pharmaceutical intermediates. It is a random polymer of four amino acids found in myelin basic protein, namely glutamic acid, lysine, alanine, and tyrosine, and may work as a decoy for the immune system. 943513-95-9 is the deleted CAS NO. of it.
Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively.
2. Basic information of Glatiramer acetate (CAS NO.147245-92-9)
1) Properties of Glatiramer acetate
(1)ACD/BCF (pH 5.5): 1.00; (2)ACD/BCF (pH 7.4): 1.00; (3)ACD/KOC (pH 5.5): 1.00; (4)ACD/KOC (pH 7.4): 1.00; (5)# of Rule of 5 Violations: 3; (6)#H bond acceptors: 18; (7)#H bond donors: 17; (8)#Freely Rotating Bonds: 19; (9)Polar Surface Area: 374.13 Å2; (10)Flash Point: 528.7 °C; (11)Enthalpy of Vaporization: 144.95 kJ/mol; (12)Boiling Point: 950.6 °C at 760 mmHg; (13)Vapour Pressure: 0 mmHg at 25°C.
2) The following information could be converted into the structure:
(1) SMILES: Oc1ccc(CC(N)C(O)=O)cc1.CC(O)=O.OC(=O)CCC(N)C(O)=O.NCCCCC(N)C(O)=O.CC(N)C(O)=O
(2) Std. InChI: InChI=1S/C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2.C2H4O2/c10-8(9(12)13)5-6-1-3-7(11)4-2-6;7-4-2-1-3-5(8)6(9)10;6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;1-2(3)4/h1-4,8,11H,5,10H2,(H,12,13);5H,1-4,7-8H2,(H,9,10);3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1H3,(H,3,4)
(3) Std. InChIKey: FHEAIOHRHQGZPC-UHFFFAOYSA-N
3) Toxicity Data of Glatiramer acetate
Adverse reactions include injection site reactions, vasodilatation, chest pain, asthenia, infection, pain, nausea, arthralgia, anxiety, and hypertonia.
4) Mechanism of action of Glatiramer acetate
Glatiramer acetate is a random polymer (average molecular mass 6.4 kD) composed of four amino acids that are found in myelin basic protein. Glatiramer acetate (GA) exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. Then it will potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression. Furthermore, the GA-specific cells in the brain express the anti-inflammatory cytokines IL-10 and transforming growth factor beta, in addition to brain-derived neurotrophic factor, however they do not express the inflammatory cytokine IFN-gamma. Some studies also suggest that Glatiramer acetate directly inhibits dendritic cells and monocytes - both of which are circulating antigen presenting cells. Glatiramer acetate has been shown in clinical trials to reduce the number and severity of exacerbations.
5) Pharmacodynamics of Glatiramer acetate
Glatiramer acetate was originally designed to mimic a protein in myelin, called myelin basic protein, with the intention of inducing EAE (an animal model of MS). Quite to the contrary, it was found to suppress the disease and as a result came to be trialed in human MS. Glatiramer acetate converts the body's immune response from a Th1 type to a Th2 one, promotes suppressor T cells or acts as an altered peptide ligand. Glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery. Some fraction of the injected material, either intact or partially hydrolyzed, is presumed to enter the lymphatic circulation, enabling it to reach regional lymph nodes, and some may enter the systemic circulation intact.
6) Applications of Glatiramer acetate
Glatiramer acetate can be used for research and clinical trials. Glatiramer acetate is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis. Glatiramer acetate is approved by the Food and Drug Administration (FDA) for reducing the frequency of relapses, but not for reducing the progression of disability. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.
7) Packaging picture of 1Kg Glatiramer acetate
COPAXONE
(glatiramer acetate) Solution for Subcutaneous Injection
(glatiramer acetate) Solution for Subcutaneous Injection
DRUG DESCRIPTION
COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE (glatiramer acetate) , consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.
COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE (glatiramer acetate) , consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.
Chemically, glatiramer acetate is designated L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt). Its structural formula is:
(Glu, Ala, Lys, Tyr)x•xCH3COOH
(C5H9NO4•C3H7NO2•C6H14N2O2•C9H11NO3)x•xC2H4O2
CAS - 147245-92-9
(C5H9NO4•C3H7NO2•C6H14N2O2•C9H11NO3)x•xC2H4O2
CAS - 147245-92-9
COPAXONE (glatiramer acetate) is a clear, colorless to slightly yellow, sterile, nonpyrogenic solution for subcutaneous injection. Each 1 mL of solution contains 20 mg of glatiramer acetate and 40 mg of mannitol. The pH range of the solution is approximately 5.5 to 7.0. The biological activity of COPAXONE (glatiramer acetate) is determined by its ability to block the induction of experimental autoimmune
Company Name: PhtdPeptides. Co., Ltd.
Contact: William wang
Email: phtd012@phtdpeptides.com
Email: phtd012@phtdpeptides.com
web: www.phtdpeptides.com
Skype: william39333
Skype: william39333
QQ:329284319
Tel : 0086-0371-65741695
Fax: 0086-0371-66837889
Mobile:0086-13592439230
Tel : 0086-0371-65741695
Fax: 0086-0371-66837889
Mobile:0086-13592439230
没有评论:
发表评论